Table S1. Sequences of *Ubx* reduction alleles

Reduction line	A30	B1	C4	E7	A31	B2	C3	
Ubx allele	ΔQA	ΔQA	ΔQA	ΔQA	+	+	+	
Position (bp)								Notes
-24	del	del	del	del	del	del	del	
-20	T	T	T	T	T	T	T	
155	A	C	A	A	A	C	A	
500	C	T	C	C	C	T	C	
532	A	C	A	A	A	C	A	
749	C	T	C	C	C	T	C	
754	G	T	G	G	G	T	G	
787	C	G	C	C	C	G	C	
819	G	C	G	G	G	C	G	
966	A	G	A	A	A	G	A	
1002	CA	GT	CA	CA	CA	GT	CA	
1007	G	A	G	G	G	A	G	
1231	G	A	G	G	G	A	G	
1382	CA	GG	CA	CA	CA	GG	CA	
3256	A	A	A	A	G	A	A	
3362	T	T	T	T	C	T	T	
3483	A	A	A	A	T	A	A	
3548	C	C	C	C	A	C	C	
3886	G	G	G	G	A	G	G	
5318	G	G	G	G	A	A	A	
5769	A	A	A	A	T	T	T	
6036	T	T	T	T	C	C	C	Introduced stop codon
6042	T	T	T	T	C	C	C	Introduced stop codon
6048	T	T	T	T	C	C	C	Introduced stop codon and *Avr* II
6051	G	G	G	G	A	A	A	Introduced *Avr* II
9146	T	T	T	C	T	C	T	
9625	A	A	A	T	A	A	A	
9786	A	A	A	del	A	A	A	
9825	G	G	G	A	G	G	G	
9941	T	T	T	A	T	T	T	
9977	GT	GT	GT	AA	GT	GT	GT	
Minimum								
crossovers	1	1	1	3	1	3	3	

Nucleotide positions are with respect to the 10,875 bp *Aat* II/*Xma* I (bp 1/bp 10875) fragment.

All other nucleotides match the sequence of the BX-C from DS03126, including several on each side not included in the targeting construct.

All polymorphisms, except the introduced four, are non-coding and not expected to impact phenotype.

Red, sequence from pTV2 targeting construct used.

Blue, sequence from targeted endogenous Ubx locus.